Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06858878 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
A Phase 3 study of Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 1,105
- Enrollment target
- 20
- Study locations
NCT06858878 is a Phase 3 study of Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight that is active but no longer recruiting, run by Amgen. The registered enrollment target is 1,105 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06858878, a Phase 3 study of Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,105 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart cafraglutide
Study Locations (20)
California
- San Fernando Valley Health Institute - Canoga Park
- Core Healthcare Group - Cerritos
- Velocity Clinical Research Chula Vista - Chula Vista
- Headlands Research California - Escondido
- Paradigm Clinical Research - Modesto
- Flourish Research - Northridge
- University of California Irvine - Orange
- Empire Clinical Research - Pomona
- Infinity Clinical Trials - San Diego
Florida
- Indago Research and Health Center - Hialeah
- Optimus U Corporation - Miami
- New Horizon Research Center - Miami
- San Marcus Research Clinic Inc - Miami Lakes
- Florida Institute for Clinical Research - Orlando
- Encore Medical Research of Weston LLC - Weston
Arizona
- Gilbert Center for Family Medicine - Gilbert
- Desert Clinical Research - Mesa
- Avacare Foothills Research Center - Phoenix
Alabama
- Alliance for Multispecialty Research Mobile - Mobile
Connecticut
- Greenwich Clinical Trials - Riverside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,105 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2027-04-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06858878
The ClinicalTrials.gov registry entry for NCT06858878 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06858878 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06858878 about?
NCT06858878 is a clinical study titled "Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight". The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
What is the current status of trial NCT06858878?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,105 participants. The study started on 2025-03-17. Estimated completion is 2027-04-16.
What conditions does trial NCT06858878 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight.
What interventions are being tested in trial NCT06858878?
The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).
Who is sponsoring clinical trial NCT06858878?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06858878 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.